Trial Profile
Influence of the Nitric Oxide Synthase T-786C Polymorphism on the Response to Acute Inhibition of Phosphodiesterase 5 in Resistant Hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sildenafil (Primary)
- Indications Resistant hypertension
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms FAPESP
- 29 Oct 2012 Primary outcome amended as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2011 New trial record